Antimyeloperoxidase antibody is a biomarker for progression of diabetic retinopathy

To study the correlation between serum antimyeloperoxidase (MPO) antibody levels with severity of diabetic retinopathy (DR). Study subjects included 60 consecutive cases of type 2 diabetes mellitus (DM): no diabetic retinopathy (NODR, n=20); nonproliferative DR (NPDR, n=20); proliferative DR (PDR, n...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and its complications 2016-05, Vol.30 (4), p.700-704
Main Authors: Sinha, Shivani, Saxena, Sandeep, Das, Siddharth, Prasad, Senthamizh, Bhasker, Shashi Kumar, Mahdi, Abbas Ali, Kruzliak, Peter
Format: Article
Language:English
Subjects:
Antimyeloperoxidase antibody
Autoantibodies - analysis
Autoimmune Diseases - blood
Autoimmune Diseases - complications
Autoimmune Diseases - immunology
Autoimmune Diseases - physiopathology
Biomarkers - blood
Cardiovascular disease
Creatinine - blood
Cross-Sectional Studies
Cytokines
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetic retinopathy
Diabetic Retinopathy - blood
Diabetic Retinopathy - immunology
Diabetic Retinopathy - physiopathology
Disease Progression
Enzyme-Linked Immunosorbent Assay
Enzymes
Gangrene
Glycated Hemoglobin A - analysis
Humans
Inflammation
Male
Medical imaging
Middle Aged
Neutrophils
Oxidative stress
Pathogenesis
Patients
Peroxidase - antagonists & inhibitors
Reproducibility of Results
Serum creatinine
Serum urea
Severity of Illness Index
Studies
Tertiary Care Centers
Tumor necrosis factor-TNF
Urea - blood
Visual Acuity
Vitreoretinopathy, Proliferative - blood
Vitreoretinopathy, Proliferative - complications
Vitreoretinopathy, Proliferative - etiology
Vitreoretinopathy, Proliferative - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To study the correlation between serum antimyeloperoxidase (MPO) antibody levels with severity of diabetic retinopathy (DR). Study subjects included 60 consecutive cases of type 2 diabetes mellitus (DM): no diabetic retinopathy (NODR, n=20); nonproliferative DR (NPDR, n=20); proliferative DR (PDR, n=20) and 20 healthy controls. Best corrected visual acuity (BCVA) was measured on logMAR scale. Serum anti-MPO antibody levels were evaluated using ELISA IgG kit. Serum urea and creatinine was measured using standard protocol. Data were analysed statistically. Mean serum anti-MPO antibody (RU/ml) was 16.94±4.85 in controls, 17.66±4.78 in NODR, 21.51±5.27 in NPDR and 37.27±11.92 in PDR groups. On ANOVA, significant difference in visual acuity was found among the study groups (F=73.46, p
ISSN:1056-8727
1873-460X
DOI:10.1016/j.jdiacomp.2016.01.010